Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levonadifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.54 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.54 |
| ▸ | TUBB | P07437 | 1/20 | 0.54 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.54 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.54 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.54 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.54 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.54 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.54 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levonadifloxacin SCHEMBL29390463 | 0.99 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Nadifloxacin SCHEMBL3818938 | 0.99 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Nadifloxacin SCHEMBL29429713 | 0.99 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Levonadifloxacin SCHEMBL36594 | 0.99 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Nadifloxacin SCHEMBL36593 | 0.99 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Levonadifloxacin SCHEMBL3972618 | 0.98 | LMNA (0.98) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Nadifloxacin SCHEMBL28112583 | 0.95 | LMNA (0.93) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL10994613 | 0.92 | LMNA (0.87) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL16518627 | 0.91 | LMNA (0.85) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL11185046 | 0.91 | LMNA (0.85) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1175217-B8 | (S)-BENZOQUINOLIZINE CARBOXYLIC ACIDS AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LTD (IN) | 2009-03-18 | — | — | EP | disclosed |
| US-6750224-B1 | USED TO SYSTEMICALLY AND TOPICALLY TREAT BACTERIAL GRAM-POSITIVE, GRAM-NEGATIVE AND ANAEROBIC INFECTIONS, ESPECIALLY RESISTANT MYCOBACTERIAL INFECTIONS AND EMERGING NOSOCOMIAL PATHOGEN INFECTIONS | WOCKHARDT LIMITED (IN) | 2004-06-15 | — | — | US | disclosed |
| EP-1175217-A2 | (S)-BENZOQUINOLIZINE CARBOXYLIC ACIDS AND THEIR USE AS ANTIBACTERIAL AGENTS | Wockhardt Limited (IN) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000068229-A2 | (S)-BENZOQUINOLIZINE CARBOXYLIC ACIDS AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LIMITED (IN) | 2000-11-16 | — | — | WO | disclosed |